Literature DB >> 16080119

Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males.

Hilde Van Esch1, Marijke Bauters, Jaakko Ignatius, Mieke Jansen, Martine Raynaud, Karen Hollanders, Dorien Lugtenberg, Thierry Bienvenu, Lars Riff Jensen, Jozef Gecz, Claude Moraine, Peter Marynen, Jean-Pierre Fryns, Guy Froyen.   

Abstract

Loss-of-function mutations of the MECP2 gene at Xq28 are associated with Rett syndrome in females and with syndromic and nonsyndromic forms of mental retardation (MR) in males. By array comparative genomic hybridization (array-CGH), we identified a small duplication at Xq28 in a large family with a severe form of MR associated with progressive spasticity. Screening by real-time quantitation of 17 additional patients with MR who have similar phenotypes revealed three more duplications. The duplications in the four patients vary in size from 0.4 to 0.8 Mb and harbor several genes, which, for each duplication, include the MR-related L1CAM and MECP2 genes. The proximal breakpoints are located within a 250-kb region centromeric of L1CAM, whereas the distal breakpoints are located in a 300-kb interval telomeric of MECP2. The precise size and location of each duplication is different in the four patients. The duplications segregate with the disease in the families, and asymptomatic carrier females show complete skewing of X inactivation. Comparison of the clinical features in these patients and in a previously reported patient enables refinement of the genotype-phenotype correlation and strongly suggests that increased dosage of MECP2 results in the MR phenotype. Our findings demonstrate that, in humans, not only impaired or abolished gene function but also increased MeCP2 dosage causes a distinct phenotype. Moreover, duplication of the MECP2 region occurs frequently in male patients with a severe form of MR, which justifies quantitative screening of MECP2 in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16080119      PMCID: PMC1226209          DOI: 10.1086/444549

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  36 in total

Review 1.  Functional disomy for Xq26.3-qter in a boy with an unbalanced t(X;21)(q26.3;p11.2) translocation.

Authors:  M Akiyama; H Kawame; H Ohashi; T Tohma; H Ohta; A Shishikura; I Miyata; N Usui; Y Eto
Journal:  Am J Med Genet       Date:  2001-03-01

2.  X-linked mental retardation with seizures and carrier manifestations is caused by a mutation in the creatine-transporter gene (SLC6A8) located in Xq28.

Authors:  Kimberly A Hahn; Gajja S Salomons; Darci Tackels-Horne; Tim C Wood; Harold A Taylor; Richard J Schroer; Herbert A Lubs; Cornelis Jakobs; Rick L Olson; Kenton R Holden; Roger E Stevenson; Charles E Schwartz
Journal:  Am J Hum Genet       Date:  2002-03-15       Impact factor: 11.025

3.  X chromosome array-CGH for the identification of novel X-linked mental retardation genes.

Authors:  Marijke Bauters; Hilde Van Esch; Peter Marynen; Guy Froyen
Journal:  Eur J Med Genet       Date:  2005 Jul-Sep       Impact factor: 2.708

4.  MECP2 is highly mutated in X-linked mental retardation.

Authors:  P Couvert; T Bienvenu; C Aquaviva; K Poirier; C Moraine; C Gendrot; A Verloes; C Andrès; A C Le Fevre; I Souville; J Steffann; V des Portes; H H Ropers; H G Yntema; J P Fryns; S Briault; J Chelly; B Cherif
Journal:  Hum Mol Genet       Date:  2001-04-15       Impact factor: 6.150

5.  Rett syndrome: clinical manifestations in males with MECP2 mutations.

Authors:  Bruria Ben Zeev; Yuval Yaron; N Carolyn Schanen; Haika Wolf; Nathan Brandt; Nathan Ginot; Ruth Shomrat; Avi Orr-Urtreger
Journal:  J Child Neurol       Date:  2002-01       Impact factor: 1.987

6.  Inherited duplication of Xq27.2-->qter: phenocopy of infantile Prader-Willi syndrome.

Authors:  E J Lammer; D R Punglia; A E Fuchs; A G Rowe; P D Cotter
Journal:  Clin Dysmorphol       Date:  2001-04       Impact factor: 0.816

7.  NXF5, a novel member of the nuclear RNA export factor family, is lost in a male patient with a syndromic form of mental retardation.

Authors:  L Jun; S Frints; H Duhamel; A Herold; J Abad-Rodrigues; C Dotti; E Izaurralde; P Marynen; G Froyen
Journal:  Curr Biol       Date:  2001-09-18       Impact factor: 10.834

Review 8.  Rett syndrome: methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations.

Authors:  R E Amir; H Y Zoghbi
Journal:  Am J Med Genet       Date:  2000

9.  MECP2 mutation in male patients with non-specific X-linked mental retardation.

Authors:  A Orrico; C Lam; L Galli; M T Dotti; G Hayek; S F Tong; P M Poon; M Zappella; A Federico; V Sorrentino
Journal:  FEBS Lett       Date:  2000-09-22       Impact factor: 4.124

Review 10.  Neural cell recognition molecule L1: relating biological complexity to human disease mutations.

Authors:  S Kenwrick; A Watkins; E De Angelis
Journal:  Hum Mol Genet       Date:  2000-04-12       Impact factor: 6.150

View more
  223 in total

1.  Severe intellectual disability and autistic features associated with microduplication 2q23.1.

Authors:  Brian H Y Chung; Sureni Mullegama; Christian R Marshall; Anath C Lionel; Rosanna Weksberg; Lucie Dupuis; Lauren Brick; Chumei Li; Stephen W Scherer; Swaroop Aradhya; D James Stavropoulos; Sarah H Elsea; Roberto Mendoza-Londono
Journal:  Eur J Hum Genet       Date:  2011-11-16       Impact factor: 4.246

2.  Long-term outcome in children with intractable epilepsy showing bilateral diffuse cortical glucose hypometabolism pattern on positron emission tomography.

Authors:  Varun Shandal; Amy L Veenstra; Michael Behen; Senthil Sundaram; Harry Chugani
Journal:  J Child Neurol       Date:  2011-09-22       Impact factor: 1.987

3.  Clan genomics and the complex architecture of human disease.

Authors:  James R Lupski; John W Belmont; Eric Boerwinkle; Richard A Gibbs
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

4.  Practical guidelines for interpreting copy number gains detected by high-resolution array in routine diagnostics.

Authors:  Nicolien M Hanemaaijer; Birgit Sikkema-Raddatz; Gerben van der Vries; Trijnie Dijkhuizen; Roel Hordijk; Anthonie J van Essen; Hermine E Veenstra-Knol; Wilhelmina S Kerstjens-Frederikse; Johanna C Herkert; Erica H Gerkes; Lamberta K Leegte; Klaas Kok; Richard J Sinke; Conny M A van Ravenswaaij-Arts
Journal:  Eur J Hum Genet       Date:  2011-09-21       Impact factor: 4.246

5.  MECP2 Duplication Syndrome.

Authors:  H Van Esch
Journal:  Mol Syndromol       Date:  2011-07-05

Review 6.  The role of MeCP2 in CNS development and function.

Authors:  Elisa S Na; Lisa M Monteggia
Journal:  Horm Behav       Date:  2010-05-31       Impact factor: 3.587

7.  A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells.

Authors:  Maria C N Marchetto; Cassiano Carromeu; Allan Acab; Diana Yu; Gene W Yeo; Yangling Mu; Gong Chen; Fred H Gage; Alysson R Muotri
Journal:  Cell       Date:  2010-11-12       Impact factor: 41.582

8.  The MeCP2/YY1 interaction regulates ANT1 expression at 4q35: novel hints for Rett syndrome pathogenesis.

Authors:  Greta Forlani; Elisa Giarda; Ugo Ala; Ferdinando Di Cunto; Monica Salani; Rossella Tupler; Charlotte Kilstrup-Nielsen; Nicoletta Landsberger
Journal:  Hum Mol Genet       Date:  2010-05-26       Impact factor: 6.150

9.  Tsix-Mecp2 female mouse model for Rett syndrome reveals that low-level MECP2 expression extends life and improves neuromotor function.

Authors:  Lieselot L G Carrette; Roy Blum; Weiyuan Ma; Raymond J Kelleher; Jeannie T Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

10.  NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2.

Authors:  Severine Durand; Annarita Patrizi; Kathleen B Quast; Lea Hachigian; Roman Pavlyuk; Alka Saxena; Piero Carninci; Takao K Hensch; Michela Fagiolini
Journal:  Neuron       Date:  2012-12-20       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.